HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 71.4%

Neg 0% Neu 0% Pos 71.4%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the price target from $20 to $25.